Title : Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial.

Pub. Date : 2011 Jan

PMID : 21273177






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In preclinical non-small-cell lung cancer (NSCLC) models, p53-dependent growth arrest after bortezomib treatment resulted in reduced cytotoxicity if bortezomib preceded docetaxel. Bortezomib tumor protein p53 Homo sapiens
2 In preclinical non-small-cell lung cancer (NSCLC) models, p53-dependent growth arrest after bortezomib treatment resulted in reduced cytotoxicity if bortezomib preceded docetaxel. Bortezomib tumor protein p53 Homo sapiens